PHP1

DOSE DISPENSED MEDICINE AND ASSOCIATED MEDICINE AND HEALTH CARE COST

PHP2

Withdrawn

PHP3

PRICING AND REIMBURSEMENT OF ORPHAN DRUGS IN ITALY

Lopatriello S¹, Schivazappa C¹, Negrini C², Berto P^1
1PBE Consulting, Verona, Italy, ²PBE Consulting, Milano, Italy

PHP4

ASSESSING THERAPEUTIC IMPROVEMENT IN CANADA AND FRANCE: A COMPARISON OF PMPRB AND ASMR CLASSIFICATIONS

Palmer WN, Dawe MV
Palmer D'Angelo Consulting Inc, Ottawa, ON, Canada

PHP5

THE PHARMACEUTICAL INDUSTRY PERSPECTIVE ON PHARMACOECONOMICS IN SAUDI ARABIA

PHP6

ESTIMATION AND COMPARISON OF OSTOMY APPLIANCE COSTS WITH REIMBURSEMENT TARIFFS IN BELGIUM

PHP7

A SURVEY OF UK HEALTHCARE WORKERS' VIEWS ON THE USE OF HANDHELD COMPUTERS IN EVIDENCE-BASED CLINICAL PRACTICE

Dickson AJ¹, Strayer SM²

¹University of Newcastle-upon-Tyne, Newcastle-upon-Tyne, UK, ²University of Virginia, Charlottesville, VA, USA

PHP8

ANTIBIOTIC UTILIZATION IN NIS REGION OF SERBIA AND MONTENEGRO

Kodela B¹, Velickovic-Radovanovic R², Lilic R², Petrovic J²

¹ Pharmacy Institution, Nis, Serbia, Serbia and Montenegro, ²Clinical Centre, Nis, Serbia, Serbia and Montenegro

PHP9

USE OF ANTIBIOTICS AT CLINICAL CENTRE OF MONTENEGRO

Goranovic S

PHP10

POTENTIAL IMPACT OF HOSPITAL DISCHARGE PRESCRIPTIONS ON COMMUNITY PRESCRIBING – AN IRISH PERSPECTIVE

Usher C, Tilson L, Barry M

PHP11

DOSE DISPENSED MEDICINE AND ASSOCIATED MEDICINE AND HEALTH CARE COST

Søndergaard B¹, Gundgaard J², Sørensen J³, Hansen EH¹

¹Danish University of Pharmaceutical Sciences, Copenhagen, Denmark, ²University of Southern Denmark, Odense C, Denmark, ³Centre for Applied Health Services Research and Technology Assessment, Odense C, Denmark

PHP12

WASTAGE OF MEDICINES IN PORTUGAL

Crisóstomo S¹, Mendes Z¹, Batel Marques F², Martins P¹, Rodrigues V³, Fontes Ribeiro C³

¹Centre for Pharmacoepidemiologic Research, National Association of Pharmacies, Lisboa, Portugal, ²Centre for Health Studies and Research, School of Economics and School of Pharmacy - University of Coimbra, Coimbra, Portugal, ³School of Medicine - University of Coimbra, Coimbra, Portugal

PHP13

BENEFIT INCIDENCE ANALYSIS BEFORE AND AFTER UNIVERSAL COVERAGE IN THAILAND

Prakongsai P, Tangcharoensathien V

PHP14

STAKEHOLDERS' PERSPECTIVES ON IMPROVING ACCESS TO PRIMARY CARE

Pumtong S, Anderson C, Boardman H

PHP15

Withdrawn

PHP16

ATTITUDES TOWARD HOME CARE AMONG ACUTELY HOSPITALIZED PATIENTS IN HUNGARY

Betlehem J¹, Török C², Sebestyén A³, Boncz I³

¹University of Pécs, Pécs, Hungary, ²District Hospital Tapolca, Tapolca, Hungary, ³National Health Insurance Fund Administration (OEP), Budapest, Hungary

PHP17

EFFICIENCY OF RHEUMATOLOGY HOSPITAL CARE: CHANGES IN THE AVERAGE LENGTH OF STAY IN RHEUMATOLOGY DEPARTMENTS IN HUNGARY

¹National Health Insurance Fund Administration (OEP), Budapest, Hungary, ²Flor Ferenc County Hospital, Kistarcsa, Hungary, ³University of Pécs, Pécs, Hungary, ⁴Corvinus University of Budapest, Budapest, Hungary

PHP18

PRICES OF GENERIC DRUGS IN FINLAND VS. EUROPE

Bergius S, Torvinen S, Hahl J

PHP19

DRUG PRICE INDICES 1980–2005 IN FINLAND

Hahl J¹, Aaltonen S², Jormanainen V³

¹GlaxoSmithKline Oy, Espoo, Finland, ²Pharma Industry Finland, Helsinki, Finland, ³Pfizer Oy, Helsinki, Finland

PHP20

SWITCH PATTERNS AROUND PATENT EXPIRY WITH ECONOMIC IMPLICATIONS FOR THE NETHERLANDS

Boersma C, Klok RM, Postma MJ

PHP21

ANALYSIS OF COST OF ILLNESS IN THE NETHERLANDS IN 2003: INTEGRATING NATIONAL AND INTERNATIONAL PERSPECTIVES ON HEALTH CARE COSTS

Slobbe LCJ, Kommer GJ, Polder JJ

PHP22

NUTRICORE®: COST-EFFECTIVENESS-ANALYSIS (CE) OF AN EVIDENCE BASED CLINICAL NUTRITION CONCEPT IN CORRELATION WITH RELEVANT CLINICAL OUTCOMES IN HOSPITALIZED MALNOURISHED PATIENTS BY RISK-ADJUSTMENT OF DIAGNOSIS BASED SEVERITY OF DISEASE

Fischer FJ, Goeke T, Gohlke A

PHP23

TIME SERIES ANALYSIS OF PHARMACEUTICAL PUBLIC EXPENDITURE: EVALUATION OF SUPPLY MEASURES

Magem Luque D¹, Gilabert i Perramon A²

¹Catalan Health Service, Barcelona, BARCELONA, Spain, ²Catalan Health Service, Barcelona, Spain

PHP24

THE COST OF ILLNESS: SPAIN 1980-2000

Gisbert R¹, Brosa M²

¹Universitat de Vic, Vic, Spain, ²Oblikue Consulting, Barcelona, Spain

PHP25

EXPENDITURES ON DRUGS IN DEVELOPED EUROPEAN COUNTRIES

Praznovcova L, Ivanovic N

PHP26

SUPPLY SIDE COST-CONTAINMENT IN GERMANY: WIN SOME, LOSE SOME

Carrera P¹ , Bridges J², Kinder K³

¹University of Heidelberg, Heidelberg, Baden-Wuertember, Germany, ²Johns Hopkins University, Baltimore, MD, USA, ³Johns Hopkins University, Nidderau, Germany

PHP27

THE ANALYSIS OF TEMPORARY WORK DISABILITY FOR THE PERIOD OF OVER 30 DAYS IN THE REPUBLIC OF SERBIA

Perovich S

PHP28

PILOT STUDY OF THE IMPACT OF NEW PRICING SCHEMA ON DRUG PRICES IN REPUBLIC SERBIA

¹ The pharmacist institution, Nish, Serbia, Serbia and Montenegro, ²The pharmacist institution, Nish, Serbia and Montenegro

PHP29

PHARMACEUTICAL BUDGET ALLOCATION: A CAPITATION MODEL

Gilabert i Perramon A¹, Magem Luque D²

¹ Catalan Health Service, Barcelona, Spain, ²Catalan Health Service, Barcelona, BARCELONA, Spain

PHP30

ASSESSING THE ECONOMIC AND SAFETY IMPACT OF GLASS VERSUS POLYMER CONTAINERS IN A RADIOLOGY DEPARTMENT

Gricar JA¹ , Harries-Jones H²

¹ Independent Health Care Consultant, New York, NY, USA, ²Poole Hospital, Poole, Dorset, UK

PHP31

THE ECONOMIC EVALUATION OF HOME PHARMACIES IN HEALTH AREA

García-Ruiz A¹, Leiva-Fernández F², Montesinos-Gálvez AC³, Avila-LaChica L⁴, Gomez-García C⁴

¹ Malaga University, Malaga, Spain, ²Unit of Teaching Family Medicine, Málaga, Spain, ³Hospital Regional Carlos Haya, Málaga, Spain, ⁴Unit of Teaching Family Medicine, Malaga, Spain

PHP32

PATIENT SATISFACTION WITH THE PHARMACY FIRST MINOR AILMENTS SCHEME

Pumtong S, Anderson C, Boardman H

PHP33

OCCUPATIONAL INJURIES: USE AND COST OF EMERGENCY DEPARTMENT FOR TREATMENT OF ACCIDENTAL HYPODERMIC NEEDLE PUNCTURES

O'Brien JA¹, Duran PA¹, Jacobs LM²

¹ Caro Research Institute, Concord, MA, USA, ²University of Connecticut, School of Medicine, Farmington, CT, USA

PHP34

PHYSICIANS' ATTITUDES TO AND EXPERIENCE WITH INCREASED USE OF INDIVIDUAL REIMBURSEMENT VERSUS GENERAL REIMBURSEMENT OF NEW IMPORTANT PHARMACEUTICALS

Levorsen A¹, Kristiansen IS², Aasland OG³

¹ Oslo University/ MSD Norway, Oslo, Norway, ²Oslo University, Oslo, Norway, ³Oslo University/ Norwegian Medical Association, Oslo, Norway

PHP35

TELEMEDICINE IN THE U.S. MEDICARE PROGRAM: 2007 REIMBURSEMENT IMPLICATIONS

Pierce CA¹ , Baker JJ², McClard C²

¹ The Resource Group, Richfield, OH, USA, ²The Resource Group, Pickton, TX, USA

PHP36

PHARMACOEPIDEMIOLOGICAL ANALYSIS OF THE USEING DRUGS FROM REIMBESMENT LIST IN RUSSIA

Yagudina RI¹, Kulikov A¹, Saffiulin R², Yarkaeva F²

¹ Moscow Medical Academy, Moscow, Russia, ²Kazan Medical University, Kazan, Russia

PHP37

GENERIC COMPETITION: EFFECT ON PRICES AND SUBSTITUTION EFFECTS

Engstrom A, Lundin D, Jacob J

PHP38

HEALTH TECHNOLOGY ASSESSMENT IN HUNGARY

Nádudvari N

PHP39

EVALUATION OF SCIENTIFIC QUALITY OF POSTMARKETING SURVEILLANCE STUDIES IN GERMANY

Dietrich ES, Zierold F

PHP40

COST-EFFECTIVENESS STUDY OF ADJUSTED CLINICAL GROUPS TO ASSESS THE ABILITY OF SPANISH PRIMARY CARE TEAMS TO BRING ISSUES TO RESOLUTION

¹ Badalona Serveis Assistencials, Barcelona, Spain, ²Badalona Servicios Asistenciales, Barcelona, Spain, ³Regió Sanitaria Barcelona. CatSalut, Barcelona, Spain

PHP41

AN ASSESMENT OF TWO IRANIAN SOCIAL SECURITY ORGANIZATION HOSPITALS PERFORMANCE BASED ON THE EFQM MODEL

Maleki MR, Izadi A

Cost Studies

PAR1

COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT VS INFLIXIMAB FOR TREATMENT OF SEVERE RHEUMATOID ARTHRITIS IN BRAZIL

Saggia MG, Pina FP

PAR2

ZOLEDRONIC ACID IN THE LONG-TERM MANAGEMENT OF PAGET'S DISEASE OF THE BONE IN GERMANY – A COST-SAVING APPROACH?

Kurth AA¹ , Kotowa W², Fricke FU², Quednau K³, Maiwenn JA⁴

¹ Orthopädische Universitätsklinik Stiftung Friedrichsheim, Frankfurt am Main, Germany, ²Fricke & Pirk GmbH - Member of the IMS Health Group, Nuremberg, Germany, ³Novartis Pharma GmbH, Nuremberg, Germany, ⁴Institute for Medical Technology Assessment, Rotterdam, The Netherlands

PAR3

AN ECONOMIC EVALUATION OF THE USE OF EXOGEN FOR FRESH AND NON-UNION FRACTURES OF THE TIBIA IN THE UK

Taylor MJ¹ , Chaplin S², Trueman P²

¹ University of York, York, UK, ²York Health Economics Consortium, York, North Yorkshire, UK

PAR4

HEALTHCARE UTILIZATION AND COSTS ASSOCIATED WITH BLUNT AND PENETRATING TRAUMA IN A UNITED STATES MANAGED CARE POPULATION

Candrilli SD¹, Davis KL¹, Joshi AV², Tortella BJ²

¹ RTI Health Solutions, Research Triangle Park, NC, USA, ²Novo Nordisk, Inc, Princeton, NJ, USA

PAR5

MODELING THE ECONOMIC AND HEALTH CONSEQUENCES OF MANAGING CHRONIC OSTEOARTHRITIS PAIN WITH ORAL OPIOIDS IN GERMANY

Ward A¹ , Copur D¹, Fleischmann J², Dubois D³, Sabatowski R⁴, Caro JJ¹

¹ Caro Research Institute, Concord, MA, USA, ²Janssen-Cilag GmbH, Neuss, Germany, ³Janssen Pharmaceutica, Beerse, Belgium, ⁴University of Cologne, Cologne, Germany

PAR6

COST-UTILITY ANALYSIS OF RITUXIMAB AS A NEW THERAPEUTIC OPTION FOR RHEUMATOID ARTHRITIS PATIENTS IN CANADA

Mistry B¹ , McCormick J², Diamantopoulos A³, Kielhorn A⁴

¹ Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ²McKesson Phase 4 Solutions, Toronto, ON, Canada, ³M-TAG UK Ltd, London, UK, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland

Health Care Use & Policy Studies

PAR7

DIFFUSION OF HEALTH TECHNOLOGIES IN DENMARK - LAGGARDS OR EARLY ADOPTERS? - FOUR CASE-STUDIES REGARDING DRIVERS AND BARRIERS

Poulsen PB¹, Vestergaard H², Aagren M³, Wickstrøm J¹, Clausen J², Pedersen Tس

¹ MUUSMANN Research & Consulting AS, Kolding, Denmark, ²The Danish Association of the Pharmaceutical Industry (Lif), Copenhagen, Denmark, ³MUUSMANN Research & Consulting AS, Copenhagen, Denmark

PAR8

TRENDS IN PRESCRIPTION CLAIMS FOLLOWING THE WITHDRAWAL OF ROFECOXIB FROM THE CANADIAN MARKET

Desjardins O¹, Manley J¹, Nanwa N¹, Goh YI², Smith RW¹, Einarson TR¹

¹ University of Toronto, Toronto, ON, Canada, ²Hospital for Sick Children, Toronto, ON, Canada

PAR9

CO-PRESCRIPTION OF GASTROPROTECTIVE AGENTS FOR PATIENTS AT RISK OF NSNSAID-INDUCED GASTROINTESTINAL HARM

Lister S¹ , Makinson G², Koncz T²

¹ Pfizer Ltd, Tadworth, Surrey, UK, ²Pfizer Limited, Tadworth, Surrey, UK

Methods & Concepts

PAR10

THE COST-UTILITY OF ADALIMUMAB (HUMIRA®) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN DENMARK

Aagren M¹ , Davies A², Pang F³, Winding B⁴

¹ MUUSMANN Research & Consulting, Copenhagen, Denmark, ²United BioSource Corporation, London, England, ³Abbott Laboratories Ltd, Maidenhead, Berks, UK, ⁴Abbott Laboratories, Gentofte, Denmark

Patient Reported Outcomes

PAR11

ARE THEY MEASURABLE? A STUDY ON ELICITING INDIRECT AND INTANGIBLE COSTS OF KNEE OSTEOARTHRITIS USING HUMAN CAPITAL APPROACH AND WILLINGNESS-TO-PAY IN MULTIETHNIC ASIAN POPULATION IN SINGAPORE

Xie F¹ , Thumboo J², Fong KY³, Lo NN³, Yeo SJ³, Yang KY³, Li SC⁴

¹ National University of Singapore, Singapore, Singapore, ²Singapore General Hospital, Singapore, Singapore, ³Singapore General Hospital, Singapore, Singapore, Singapore, ⁴National University of Singapore, Singapore, Singapore, Singapore

Clinical Outcomes Studies

PDB1

BETTER HBA1C CONTROL WITH BOT VERSUS CT AVOIDS LONG-TERM MICRO-VASCULAR COMPLICATIONS IN PATIENTS WITH TYPE-2-DIABETES: MODEL SIMULATIONS WITH THE DMM

Walzer S¹ , Huppertz E², Mueller E¹, Janka HU³

¹ Analytica International, Loerrach, Germany, ²Sanofi-Aventis Deutschland GmbH, Berlin, Germany, ³Zentralkrankenhaus Bremen-Nord, Bremen, Germany

PDB2

AN EVALUATION OF DIABETES CONTROL AND REPORTS OF HYPOGLYCAEMIA IN UK GENERAL PRACTICE FOLLOWING INITIATION OF INSULIN GLARGINE VERSUS INSULIN DETEMIR USING OBSERVATIONAL, REAL-LIFE DATA

Currie CJ¹ , Tetlow AP², Holmes P³, Poole CD², McEwan P¹

¹ Cardiff University, Cardiff, South Glamorgan, UK, ²Cardiff Research Consortium, Cardiff, South Glamorgan, UK, ³sanofi-aventis UK, Guildford, Surrey, UK

Cost Studies

PDB3

THE COST-BENEFIT OF KERRABOOT USE IN DIABETIC FOOT ULCER MANAGEMENT

Knight AD¹ , Sexton O²

¹ Evicom Ltd, Twickenham, Middlesex, UK, ²Ark Therapeutics Group plc, London, Middlesex, UK

PDB4

AN EVALUATION OF THE COST OF DIABETES-RELATED MEDICATION FOLLOWING INITIATION OF TREATMENT WITH INSULIN GLARGINE VERSUS INSULIN DETEMIR IN THE UK FROM OBSERVATIONAL, REAL-LIFE DATA FROM GENERAL PRACTICE

Poole CD¹, Tetlow AP¹, Holmes P², McEwan P³, Currie CJ³

¹ Cardiff Research Consortium, Cardiff, South Glamorgan, UK, ²sanofi-aventis UK, Guildford, Surrey, UK, ³Cardiff University, Cardiff, South Glamorgan, UK

PDB5

PREVENTION WITH PICOTAMIDE AND ASPIRIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND PERIPHERAL ARTERIAL DISEASE: A PHARMACOECONOMIC EVALUATION

Iannazzo S¹, Pradelli L¹, Eandi M²

¹ Advanced Research Srl, Turin, Italy, ²Università di Torino, Turin, Italy

PDB6

COST-EFFECTIVENESS OF THE ONE-TOUCH^® ULTRASMART^® BLOOD GLUCOSE METER COMPARED WITH A CONVENTIONAL METER FOR INSULIN-USING DIABETES PATIENTS FROM THE USA

Minshall ME¹, Palmer AJ², Valentine WJ²

¹ IMS, Fishers, IN, USA, ²IMS, Allschwil, Switzerland

PDB7

THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN IN THE UK IN PEOPLE WITH TYPE 1 DIABETES

McEwan P¹ , Poole CD², Holmes P³, Tetlow AP², Currie CJ¹

¹ Cardiff University, Cardiff, South Glamorgan, UK, ²Cardiff Research Consortium, Cardiff, South Glamorgan, UK, ³sanofi-aventis UK, Guildford, Surrey, UK

PDB8

THE IMPACT OF IMPROVED BETA-CELL FUNCTION ON MODELLING THE COST-EFFECTIVENESS OF ROSIGLITAZONE IN THE MANAGEMENT OF TYPE 2 DIABETES IN SPAIN

Shearer A¹, Bagust A², Ampudia-Blasco FJ³, Taylor MJ⁴, Mendes da Costa S⁵

¹ GlaxoSmithKline, London, UK, ²University of Liverpool, Liverpool, UK, ³Clinic University Hospital, Valencia, Spain, ⁴University of York, York, UK, ⁵GlaxoSmithKline, Uxbridge, UK

PDB9

THE ECONOMIC BENEFIT OF SELF-MONITORING OF BLOOD GLUCOSE (SMBG) IN TYPE 2 NON INSULIN TREATED DIABETES PATIENTS IN SWITZERLAND

Holm MV, Schwenkglenks M, Szucs TD

PDB10

LONG-TERM CLINICAL AND ECONOMIC OUTCOMES FOR PATIENTS WITH TYPE 1 DIABETES TREATED WITH INSULIN ASPART VERSUS HUMAN SOLUBLE INSULIN IN SWEDEN

Tucker D¹ , Brandt AS², Foos V¹, Munro V³, Goodall G¹, Ray J¹, Valentine WJ¹, Roze S¹, Palmer AJ¹

¹ CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland, ²Novo Nordisk Scandinavia AB, Malmo, Sweden, ³Novo Nordisk Ltd, Crawley, West Sussex, UK

PDB11

LONG-TERM COST-EFFECTIVENESS ANALYSIS OF REPAGLINIDE VERSUS NATEGLINIDE IN COMBINATION WITH METFORMIN IN TYPE 2 DIABETES PATIENTS FAILING MONOTHERAPY IN THE SWEDISH SETTING

Ray J¹ , Brandt AS², Foos V¹, Munro V³, Valentine WJ¹, Roze S¹, Palmer AJ¹

¹ CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland, ²Novo Nordisk Scandinavia AB, Malmo, Sweden, ³Novo Nordisk Ltd, Crawley, West Sussex, UK

PDB12

CONTINUOUS SUBCUTANEOUS INSULIN INFUSION VERSUS MULTIPLE DAILY INJECTION OF INSULIN IN PATIENTS WITH TYPE 1 DIABETES: A LONG-TERM HEALTH ECONOMIC ANALYSIS IN THE NORWEGIAN AND SWEDISH SETTINGS

Goodall G¹ , Nicklasson L², Zakrzewska K³, Foos V¹, Valentine WJ¹, Roze S¹, Palmer AJ¹

¹ CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland, ²Medtronic AB, Järfälla, Sweden, ³Medtronic AG, Tolochenaz, Switzerland

PDB13

THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN IN THE UK IN PEOPLE WITH TYPE 2 DIABETES

McEwan P¹ , Tetlow AP², Holmes P³, Poole CD², Currie CJ¹

¹ Cardiff University, Cardiff, South Glamorgan, UK, ²Cardiff Research Consortium, Cardiff, South Glamorgan, UK, ³sanofi-aventis UK, Guildford, Surrey, UK

PDB14

DIRECT COST FOR CONTROL OF DM IN A RURAL AREAS

Avila-LaChica L¹, Leiva-Farnández F², García-Ruiz A³, Gomez-García C¹, Montesinos-Gálvez AC⁴

¹ Unit of Teaching Family Medicine, Malaga, Spain, ²Unit of Teaching Family Medicine, Málaga, Spain, ³Malaga University, Malaga, Spain, ⁴Hospital Regional Carlos Haya, Málaga, Spain

PDB15

SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES: COST UTILITY ANALYSIS IN AN ITALIAN SETTING

Palmer AJ¹ , Minshall ME², Valentine WJ¹, Foos V¹, Tunis SL²

¹ IMS, Allschwil, Switzerland, ²IMS, Fishers, IN, USA

PDB16

SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES: COST UTILITY ANALYSIS IN A FRENCH GOVENMENT PAYER SETTING

Palmer AJ¹ , Minshall ME², Valentine WJ¹, Foos V¹, Tunis SL²

¹ IMS, Allschwil, Switzerland, ²IMS, Fishers, IN, USA

PDB17

SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES: COST UTILITY ANALYSIS IN A GERMAN GOVENMENT PAYER SETTING

Palmer AJ¹ , Minshall ME², Valentine WJ¹, Foos V¹, Tunis SL²

¹ IMS, Allschwil, Switzerland, ²IMS, Fishers, IN, USA

PDB18

COST-EFFECTIVENESS OF ACARBOSE IN PATIENTS WITH TYPE-2 DIABETES IN THREE COUNTRIES

Evers T¹ , Roze S², Palmer AJ², Valentine WJ², Tucker D², Hanefeld M³

¹ Bayer Healthcare AG, Wuppertal, Germany, ²CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Switzerland, ³GWT TU Dresden, Dresden, Germany

PDB19

COMPARATIVE OUTCOMES-BASED HEALTH ECONOMIC EVALUATION OF TYPE 2 DIABETES PATIENTS ON BASAL INSULIN ANALOGS

Cobden D¹ , Valentine WJ², Koenen C¹, Palmer AJ², Roze S³

¹Novo Nordisk Inc, Princeton, NJ, USA, ²CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland, ³CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Switzerland

PDB20

THERAPY CLASS CONVERSION IN PATIENTS WITH TYPE 2 DIABETES: ECONOMIC EVALUATION OF INSULIN DETEMIR AND NPH

¹CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland, ²Novo Nordisk Inc, Princeton, NJ, USA, ³CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Switzerland

PDB21

ECONOMIC EVALUATION OF INITIATING INSULIN DETEMIR AMONG TYPE 2 DIABETES PATIENTS RECEIVING ORAL MEDICATION

¹CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland, ²Novo Nordisk Inc, Princeton, NJ, USA, ³CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Switzerland

PDB22

EVALUATING THE LONG-TERM HEALTH OUTCOMES AND ECONOMICS OF INITIATING BIPHASIC ANALOG INSULIN COMPARED TO OPTIMIZED ORAL THERAPY ALONE

¹ CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland, ²Novo Nordisk Inc, Princeton, NJ, USA

PDB23

THE COST-EFFECTIVENESS OF INHALED INSULIN IN SWEDEN

Neovius M¹ , Prüz C²

¹Karolinska University Hospital, Stockholm, Sweden, ²Pfizer AB, Stockholm, Sweden

PDB24

COST OF A MAJOR HYPOGLYCAEMIC EVENT IN TYPE 1 AND TYPE 2 DIABETIC PATIENTS - A SYSTEMATIC LITERATURE REVIEW

Lilja U¹ , Asmussen M², Lindgren P¹

¹ Stockholm Health Economics, Stockholm, Sweden, ²Novo Nordisk, Bagsvaerd, Denmark

PDB25

COST OF INPATIENT AND OUTPATIENT CARE OF SWEDISH PATIENTS WITH DIABETES MELLITUS

Ringborg A¹, Berwick S¹, Stålhammar J², Martinell M², Lindgren P¹

¹ European Health Economics, Stockholm, SE, Sweden, ²Uppsala University, Uppsala, Sweden

PDB26

COST-EFFECTIVENESS OF ROSIGLITAZONE FOR TREATMENT OF TYPE 2 DIABETES IN PORTUGAL USING DIFFERENT METHODS TO MODEL CLINICAL EFFECTS

¹ University of York, York, UK, ²University of Liverpool, Liverpool, Liverpool, UK, ³National School Public Health, Nova University Lisbon, Lisboa, Portugal, ⁴GlaxoSmithKline, Uxbridge, Middlesex, UK, ⁵University of York, York, North Yorks, UK, ⁶GlaxoSmithKline, London, UK

PDB27

A COST-UTILITY ANALYSIS OF ORLISTAT (XENICAL®) IN THE TREATMENT OF DIABETIC PATIENTS WITH MORBID OBESITY AND ADDITIONAL CVD RISK IN NORWAY

Sverre JM, Kristensen FKO, Holm LB, Nyhus K

PDB28

INADEQUATE GLYCEMIC CONTROL: IS IT RELATED WITH MORE COMORBIDITIES AND MORE RESOURCE UTILIZATION?

Sicras A¹, Navarro R¹, González P², Sánchez C², F Bobadilla J², Soto J²

¹ Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, ²Pfizer Spain, Alcobendas, Madrid, Spain

Health Care Use & Policy Studies

PDB29

COMPARING THE DEVELOPMENT OF A GERMAN DIABETES POPULATION WITH RESPECT TO LONGTERM OUTCOMES USING DATA FROM THE DETECT STUDY AND THE EAGLE DIABETES SIMULATION MODEL

Mueller E¹, Walzer S¹, Pieper L², Klotsche J², Stridde E³

¹ Analytica International, Loerrach, Germany, ²Technische Universität Dresden, Dresden, Germany, ³Pfizer Pharma GmbH, Karlsruhe, Germany

PDB30

DRUGS USE IN DIABETIC PATIENTS

Cammarota S¹, De Portu S², Menditto E¹, Stefanini G¹, Mantovani LG²

¹ University of Naples, Federico II, Naples, Naples, Italy, ²University of Naples, Federico II, Naples, Naples, Italy

PDB31

Withdrawn

PDB32

AMPUTATIONS IN DIABETIC FOOT ULCER PATIENTS USING NPWT

Keith MS¹, Dhanda R¹, Boulton AJ²

Methods & Concepts

PDB33

THE EFFICACY OF INSULIN GLARGINE COMPARED TO OTHER INJECTABLE THERAPIES - A META-ANALYSIS OF CLINICAL OUTCOMES IN INSULIN NAÏVE TYPE 2 DIABETES PATIENTS

¹ M-TAG Ltd, a unit of IMS, London, UK, ²Eli Lilly and Company, Indianapolis, IN, USA, ³formerly of M-TAG Limited, a unit of IMS, London, UK

PDB34

A POPULATION-BASED STUDY OF THE TIME TO INSULIN INITIATION/ INTENSIFICATION AFTER FAILURE ON CURRENT THERAPY IN PATIENTS WITH TYPE1 AND TYPE 2 DIABETES IN THE UK

Calvert MJ, Freemantle N, McManus RJ

PDB35

COST-EFFECTIVENESS OF INHALED INSULIN IN PATIENTS WITH DIABETES UNCONTROLLED ON THEIR CURRENT THERAPY: THE UK BASE CASE SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE)

Plun-Favreau J, O'Regan C, Marchant N

PDB36

THE TRANSLATION AND LINGUISTIC VALIDATION OF THE SATISFACTION WITH ORAL ANTI-DIABETIC AGENTS (SOADA) QUESTIONNAIRE

Houchin C¹, Wild D¹, Horblyuk R²

¹ Oxford Outcomes Ltd, Oxford, Oxfordshire, UK, ²GlaxoSmithKline, Philadelphia, PA, USA

Patient Reported Outcomes

PDB37

SCORING AND PSYCHOMETRIC VALIDATION OF A SCALE FOR DIABETIC PATIENT PROFILING BASED ON PATIENT ATTITUDE TOWARDS INSULIN

Arnould B¹, Bosch V¹, Benmedjahed K¹, Guéron B², Consoli S³, Martinez L⁴, Wong O⁵, Yomtov B⁶, Simon D⁷, Monnier L⁸

¹ Mapi Values France, Lyon, France, ²Pfizer, Paris, France, ³HEGP Hospital, Paris, France, ⁴French Society of General Practitioners, Bois d'Arcy, France, ⁵Cabinet Medical, Paris, France, ⁶Henri Mondor Hospital, Charenton-le-Pont, France, ⁷La Pitié-Salpêtrière Hospital, Paris, France, ⁸Lapeyronie Hospital, Montpellier, France

PDB38

ADHERENCE TO STATIN TREATMENT IN PEOPLE WITH TYPE 1 AND TYPE 2 DIABETES

Donnan PT, Donnelly L, Morris A

PDB39

THE IMPACT ON QUALITY OF LIFE BY CONVERTING THE TREATMENT OF TYPE 2 DIABETIC PATIENTS FROM CONVENTIONAL INSULIN REGIMENT TO ORAL TREATMENT WITH PIOGLITAZONE

¹ Universität Bielefeld, Bielefeld, Germany, ²University of Bielefeld, Bielefeld, NRW, Germany

PDB40

HEALTH-RELATED QUALITY OF LIFE OF TYPE 2 DIABETICS IN GERMAN PRIMARY CARE: RESULTS OF THE DETECT STUDY

Pieper L¹, Klotsche J¹, Jacobi F¹, Pittrow D¹, Böhler S¹, Lehnert H², Wittchen HU¹

¹ Technische Universität Dresden, Dresden, Germany, ²University of Warwick, Coventry, UK

PDB41

EFFECT OF COMPLICATIONS ON HEALTH RELATED QUALITY OF LIFE IN HUNGARIAN INSULIN TREATED DIABETIC PATINETS

¹Corvinus University of Budapest, Budapest, Hungary, ²Flor Ferenc County Hospital, Kistarcsa, Hungary

PDB42

PATIENT AND PHYSICIAN DRIVERS OF HEALTH-RELATED QUALITY LIFE OF PATIENTS WITH TYPE 2 DIABETES IN PRIMARY CARE IN SPAIN

¹ Eli Lilly and Company, Indianapolis, IN, USA, ²Health Outcomes Research Europe, Barcelona, Spain, ³Eli Lilly Spain, Alcobendas, Spain

PDB43

Withdrawn

PDB44

EXPLORING DIFFERENCES IN PATIENT VERSUS PUBLIC PREFERENCES IN HEALTH UTILITIES: A QUALITATIVE STUDY

loyd A¹, Nafees B², Rousculp M³, Girach A⁴, Ahmad A⁵

¹ United Biosource Corporation, London, UK, ²UBC, London, UK, ³Eli Lilly and Company, Indianapolis, IN, USA, ⁴Eli Lilly and Company, Surrey, UK, ⁵Royal Liverpool University Hospital, Liverpool, UK

PDB45

EXPERIENCE OF HYPOGLYCEMIA IS SIGNIFICANTLY ASSOCIATED WITH LOWER QUALITY OF LIFE (EUROQOL) IN DIABETIC PATIENTS TREATED WITH METFORMIN (MF) IN COMBINATION WITH A SULPHONYLUREA (SU) IN FRANCE

Mavros P, Lyu R, Yin D

PDB46

QUANTIFYING THE IMPACT OF FEAR OF HYPOGLYCAEMIA ON QUALITY OF LIFE

¹ M-TAG Pty Ltd - A unit of IMS Health®, Chatswood, NSW, Australia, ²Sanofi-aventis Australia, Macquarie Park, NSW, Australia

PDB47

A USEFUL TOOL FOR EVALUATING THE FEAR OF INJECTING AND SELF-TESTING IN DIABETIC PATIENTS: THE SPANISH VERSION OF THE DIABETES FEAR OF INJECTING AND SELF-TESTING QUESTIONNAIRE (D-FISQ)

Rebollo P¹, González P², Baillo P³, Laporta F⁴, Martorell J⁵, Morís J¹, Rejas J²

¹ BAP Health Outcomes, Oviedo, Asturias, Spain, ²Pfizer Spain, Alcobendas, Madrid, Spain, ³C.A.P. Cervera, Cervera, Lleida, Spain, ⁴C.S. La Roda, La Roda, Albacete, Spain, ⁵C.A.P. Guissona, Guissona, Lleida, Spain

PDB48

MANAGEMENT AND TREATMENT ADHERENCE IN TYPE 2 DIABETIC PATIENTS IN SPAIN

Secnik K<¹ , Yurgin NR¹, Lara N², Badia X², Dilla T³, Cordero LA³

¹ Eli Lilly and Company, Indianapolis, IN, USA, ²Health Outcomes Research Europe, Barcelona, Spain, ³Eli Lilly Spain, Alcobendas, Spain

PDB49

TREATMENT SATISFACTION WITH INSULIN GLARGINE AND INSULIN GLULISINE IN DIABETES MELLITUS - EVALUATED IN AN OBSERVATIONAL STUDY IN GERMANY

¹ Specialist in Internal Medicine, Diabetologist, Sinsheim, Germany, ²Sanofi-Aventis Germany GmbH, Bad Soden, Germany, ³Sanofi-Aventis Germany GmbH, Berlin, Germany

PDB50

MYTHS AND REALITIES OF TREATMENT SATISFACTION IN DIABETES

Brod M¹ , Cobden D², Lammert M³, Bushnell D⁴

¹ The BROD GROUP, Mill Valley, CA, USA, ²Novo Nordisk Inc, Princeton, NJ, USA, ³Novo Nordisk, Copenhagen, Denmark, ⁴Health Research Associates, Mountlake Terrace, WA, USA

Clinical Outcomes Studies

PEN1

DETERMINATION OF THE TOTAL COST OF DIAGNOSTIC PROCEDURE BY FINE NEEDLE ASPIRATION CYTOLOGY IN PATIENTS WITH THYROID NODULES

Borget I, Vielh P, Schlumberger M, De Pouvourville G

Cost Studies

PEN2

COST COMPARISON OF HUMAN GROWTH HORMONE DELIVERED VIA PEN DEVICES AND VIAL/SYRINGE IN PEDIATRIC PATIENTS: A BUDGETARY IMPACT MODEL

Bazalo GR¹ , Joshi AV², Germak JA³

¹ Managed Solutions, LLC, Conifer, CO, USA, ²Novo Nordisk Pharmaceuticals, Inc, Princeton, NJ, USA, ³Novo Nordisk Pharmaceuticals, Princeton, NJ, USA

PEN3

COST COMPARISON OF HUMAN GROWTH HORMONE DELIVERED VIA PEN DEVICES VERSUS VIAL/SYRINGE IN ADULT PATIENTS: A BUDGETARY IMPACT MODEL

Bazalo GR¹ , Joshi AV², Germak JA³

¹ Managed Solutions, LLC, Conifer, CO, USA, ²Novo Nordisk, Inc, Princeton, NJ, USA, ³Novo Nordisk Pharmaceuticals, Princeton, NJ, USA

Patient Reported Outcomes

PEN4

EVALUATION OF THE ASSOCIATION BETWEEN THE QUALITY OF LIFE, SOCIAL CLASS AND HEIGHT IN THE GENERAL ADULT UK POPULATION

Christensen T¹, Djuurhus C¹, Andersen S², Kragh N², Clayton P³, Christiansen J⁴

¹ Novo Nordisk, Bagsvaerd, Denmark, ²University of Southern Denmark, Odense, Denmark, ³University of Manchester, Manchester, UK, ⁴Århus University Hospital, Århus, Denmark

Clinical Outcomes Studies

PGI1

IS COMBINATION THERAPY OF LAMIVUDINE WITH INTERFERON-ALPHA SUPERIOR TO LAMIVUDINE MONOTHERAPY FOR HBEAG-POSITIVE CHRONIC HEPATITIS B? A META-ANALYSIS OF RANDOMIZED TRIALS.

Sun X¹ , Zhou R², Li Y¹, Zhao L³

¹ West China Hospital, Sichuan University, Chengdu, China, ²West China Medical School, Chengdu, China, ³Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China

PGI2

PROTON PUMP INHIBITORS FOR THE TREATMENT OF REFLUX OESOPHAGITIS: ENDOSCOPIC HEALING RATES FROM A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS

Edwards SJ¹, Lind T², Lundell L³

¹ AstraZeneca UK Ltd, Luton, Bedfordshire, UK, ²AstraZeneca R&D Mölndal, Mölndal, Västra Götaland, Sweden, ³Karolinska University Hospital, Stockholm, Huddinge, Sweden

PGI3

EFFICACY OF ESOMEPRAZOL IN GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD) IN A MEXICAN POPULATION

Ballesteros A¹, Bandera J², Orozco A³, Perez J⁴, Rincon V⁵, Soto H⁶, Valdovinos F⁷, Vargas A⁸

¹ Angeles Pedregal Hospital, Mexico D.F, México D.F, Mexico, ²National Institute of Nutrition Salvador Zubiran (INNSZ), Tlalpan, México D.F, Mexico, ³Saint Mary Hospital, Guadalajara, Guadalajara, Mexico, ⁴Spanish Hospital, Ciudad de México, México D.F, Mexico, ⁵Astra Zeneca, Naucalpan, Edo. de Mex, Mexico, ⁶Astra Zeneca México, Naucalpan, Estado de México, Mexico, ⁷Nacional Institute of Nutrition Salvador Zubiran (INNSZ), Tlalpan, Mexico D.F, Mexico, ⁸General Hospital of Mexico, Mexico D.F, México D.F, Mexico

PGI4

ESOMEPRAZOLE VERSUS OTHER PROTON-PUMP INHIBITORS (PPI): CLINICAL AND COST EFFECTIVENESS ANALYSIS

PGI5

GASTROINTESTINAL MEDICATION USE AND COSTS IN HEART TRANSPLANT RECIPIENTS RECEIVING MYCOPHENOLATE MOFETIL

Legorreta AP¹, Gilmore AS², Marehbian J², Naujoks C³, Kilburg A³

¹ UCLA School of Public Health, Los Angeles, CA, USA, ²Health Benchmarks, Inc, Woodland Hills, CA, USA, ³Novartis Pharma AG, Basel, Switzerland

Cost Studies

PGI6

THE USE OF BUDGET IMPACT MODELLING TO ASSESS THE ECONOMIC CONSEQUENCE OF CHANGING THE PRESCRIPTION PATTERN OF PROTON PUMP INHIBITORS (PPI) IN SWEDEN.

Hjelmgren J¹, Persson U²

¹ The Swedish Institute for Health Economics, IHE, Lund, Sweden, ²The Swedish Institute for Health conomics, IHE, Lund, Sweden

PGI7

COST-EFFECTIVENESS OF A POTENTIAL FUTURE HELICOBACTER PYLORI VACCINE IN THE NETHERLANDS

De Vries R¹, Klok RM¹, Brouwers J¹, Postma MJ²

¹ University of Groningen, Groningen, The Netherlands, ²University of Groningen / Groningen University Institute for Drug Exploration (GUIDE), Groningen, The Netherlands

PGI8

COST-EFFECTIVENESS ANALYSIS OF ROTAVIRUS VACCINATION PROGRAMME IN THE UK

Largeron N¹, Trichard M², Miadi-Fargier H³, Trancard A³, D’Ausilio A⁴, Chicoye A⁵

¹ sanofi pasteur MSD, Lyon, France, ²sanofi pasteur MSD, Lyon, France, France, ³AREMIS - aegisnet, Neuilly sur Seine, France, ⁴Fourth Hurdle - aegisnet, London, UK, ⁵AREMIS - aegisnet, Neuilly-sur-Seine, France

PGI9

FIBRIN-COATED COLLAGEN FLEECE PATCHES OR FIBRIN GLUE? CLINICAL OUTCOMES FOLLOWING LIVER RESECTION SHOW NO DIFFERENCES

Schön MR, Kaps MD, Hauss JP

PGI10

COST-EFFECTIVENESS OF ESOMEPRAZOLE VERSUS GENERIC OMEPRAZOLE IN THE ACUTE TREATMENT OF REFLUX ESOPHAGITIS IN GERMANY

Wahlqvist P¹, Reinhold T²

¹ AstraZeneca R&D, Mölndal, Sweden, ²Charité University Medical Center, Berlin, Germany

PGI11

ECONOMIC EVALUATION OF THE PHARMACOLOGICAL THERAPY OF BLEEDING ESOPHAGEAL VARICES IN MEXICO

Garcia-Contreras F¹, Constantino-Casas P¹, Nevarez-Sida A¹, Del Angel-García G², García-Constantino M², Rojas-Martínez E²

¹ Mexican Institute of Social Security, México, Distrito Federal, Mexico, ²Instituto Mexicano del Seguro Social, México City, Mexico City, Mexico

Health Care Use & Policy Studies

PGI12

GASTROINTESTINAL COMPLICATIONS INDUCED BY NON-STERIODAL ANTI-INFLAMMATORY DRUGS (NSAID): EPIDEMIOLOGICAL EXTRAPOLATION FOR EUROPE AND ECONOMIC CONSIDERATIONS

Sterzel A¹ , Grass U², Berger K³, Plesnila-Frank C³

¹ Altana Pharma AG, Konstanz, Germany, ²Altana Pharma Deutschland GmbH, Konstanz, Germany, ³MERG-Medical Economics Research Group, Munich, Germany

Methods & Concepts

PGI13

ECONOMIC EVALUATION OF THE ARTIFICIAL LIVER SUPPORT SYSTEM MARS IN PATIENTS WITH ACUTE-ON-CHRONIC LIVER FAILURE – FINAL RESULTS OF A CLINICAL COHORT TRIAL

Hessel FP

PGI14

COMPARATIVE EFFICACY OF PARIET (RABEPRAZOLE): LESSONS FROM CLAIMS DATA

Glass JR¹ , Rocchi A², Lelorier J³

¹ Janssen-Ortho Inc, Toronto, ON, Canada, ²Axia Research, Hamilton, ON, Canada, ³Universite de Montreal, Montreal, QC, Canada

Patient Reported Outcomes

PGI15

HEALTH-STATE UTILITIES IN LIVER DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

McLernon DJ, Dillon JF, Donnan PT

PGI16

ARE ADULTS MORE AVERSE TO TREATMENT RISKS FOR THEIR CHILDREN THAN THEY ARE FOR THEMSELVES?

Johnson FR¹, Ozdemir S¹, Mansfield C¹, Hass SL², White TJ²

¹ RTI International, Research Triangle Park, NC, USA, ²Elan Pharmaceuticals Inc, San Diego, CA, USA

PGI17

DEPICTION OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) PREVALENCE IN PRIMARY CARE IN GREECE

¹ Ippokration General Hospital, Athens, Greece, ²AstraZeneca SA, Athens, Greece

PGI18

DISCRIMINANT VALIDITY OF THE WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE IN PATIENTS WITH CROHN'S DISEASE

¹ Margaret Reilly Associates, Inc, New York, NY, USA, ²Keyrus Biopharma, Levallois Perret, France, ³UCB, Slough, UK

PGI19

A COMMUNITY PERSPECTIVE ON THE EFFECT OF GASTROESOPHAGEAL REFLUX DISEASE ON PRODUCTIVITY WHILE AT WORK IN FRANCE

Wahlqvist P¹, Ducrotté P²

¹ AstraZeneca R&D, Mölndal, Sweden, ²Rouen University Hospital, Mont Saint Aignan, France

Patient Reported Outcomes

PGI20

THE ASSOCIATION BETWEEN WORK PRODUCTIVITY AND RESPONSE TO PROTON PUMP INHIBITOR THERAPY IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE

Wahlqvist P¹, Ducrotté P², Jones R³, Liker H⁴

¹ AstraZeneca R&D, Mölndal, Sweden, ²Rouen University Hospital, Mont Saint Aignan, France, ³Kings College, London, UK, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Cost Studies

PHM1

COST-EFFECTIVENESS OF REGULAR CONTINUOUS PROPHYLACTIC TREATMENT IN ADULT PATIENTS WITH SEVERE HEMOPHILIA A

Monzini MS¹, Gringeri A², Ravera S³, Mantovani LG⁴

¹ University of Milan, Milan, Italy, ²Regina Elena Hosp. and Univ. of Milan, Milan, Italy, ³Center of Pharmacoeconomics, University of Milan, Milan, Italy, Italy, ⁴University of Naples, Federico II, Naples, Naples, Italy

PHM2

INPATIENT RESOURCE USE AND COSTS OF TRAUMA IN PATIENTS WITH VS WITHOUT BLOOD TRANSFUSION: EVIDENCE FROM THE HEALTHCARE COST AND UTILIZATION PROJECT DATABASE

¹ Boston Health Economics, Inc, Waltham, MA, USA, ²Novo Nordisk, Inc, Princeton, NJ, USA, ³Tufts University School of Medicine, Boston, MA, USA

PHM3

HEPARIN-RELATED THROMBOCYTOPENIA ASSOCIATED WITH MAJOR INCREASE IN HOSPITAL COSTS

Eisenstein EL, Honeycutt EF, Anstrom KJ, Granger CB, Becker RC, Ohman EM

PHM4

Withdrawn

PHM5

ECONOMIC ANALYSIS OF SURGICAL INTERVENTIONS IN ROMANIAN HAEMOPHILIACS

Mihailov MD¹, Serban M², Badeti R³, Popescu B⁴, Tepeneu P⁵, Schramm W⁶

¹ University Of Medicine and Pharmacy "Victor Babes", Timisoara, Timis, Romania, ²University of Medicine and Pharmacy, Timisoara, Romania, ³Children Hospital, Timisoara, Romania, ⁴Children Hopsital, Timisoara, Romania, ⁵University of Medicine and Pharmacy "Vitctor Babes" Timisoara, Timisoara, Romania, ⁶"Ludwig-Maximillians” -University, Munich, GA, Germany

PHM6

SOCIETAL COSTS OF ALLOGENEIC BLOOD TRANSFUSION IN THE NETHERLANDS

Van Hulst M¹, Klok RM², Eschbach ME³, Postma MJ⁴

¹ Groningen University Institute for Drug Exploration / Martini Hospital, Groningen, The Netherlands, ²University of Groningen, Groningen, Groningen, The Netherlands, ³University of Groningen / Groningen Institute for Drug Exploration, Groningen, The Netherlands, ⁴University of Groningen / Groningen University Institute for Drug Exploration (GUIDE), Groningen, Groningen, The Netherlands

PHM7

DIRECT COST OF BETA THALASSEMIA MAJOR: RESUTS FROM THE ITHACA STUDY

Mantovani LG¹, Ravera S², Scalone L³, Cappellini M⁴

¹ University of Naples, Federico II, Naples, Naples, Italy, ²Center of Pharmacoeconomics, University of Milan, Milan, Italy, Italy, ³University of Milan, Milan, Milan, Italy, ⁴Congenital Anemia Center, IRCSS Foundation Policlinico, Mangiagalli, Regina Elena Hospitals and University of Milan, Milan, Italy

PHM8

INDIRECT COSTS OF BETA THALASSEMIA MAJOR: RESULTS FROM THE ITACA STUDY

¹ The institute for Medical Technology Assessment, Rotterdam, The Netherlands, ²Center of Pharmacoeconomics, University of Milan, Milan, Italy, ³IMTA, Rotterdam, The Netherlands, ⁴Congenital Anemia Center, IRCSS Foundation Policlinico, Mangiagalli, Regina Elena Hospitals and University of Milan, Milan, Italy, ⁵University of Milan, Milan, Italy, ⁶University of Naples, Federico II, Naples, Italy

Methods & Concepts

PHM9

THE EVALUATION OF ECONOMIES OF SCOPE IN GENETIC SCREENING BY DNA TECHNOLOGY: A MODELING STUDY

Rogowski W

Patient Reported Outcomes

PHM10

QUALITY OF LIFE IN PATIENTS WITH BETA THALASSEMIA MAJOR: RESULTS FROM THE ITHACA STUDY

Mantovani LG¹, Ravera S², Scalone L³, Cappellini M⁴

¹ University of Naples, Federico II, Naples, Italy, ²Center of Pharmacoeconomics, University of Milan, Milan, Italy, Italy, ³University of Milan, Milan, Milan, Italy, ⁴Congenital Anemia Center, IRCSS Foundation Policlinico, Mangiagalli, Regina Elena Hospitals and University of Milan, Milan, Italy

PHM11

DEVELOPMENT AND SCORING OF THE SATISFACTION WITH IRON CHELATION THERAPY INSTRUMENT FOR PATIENTS WITH IRON OVERLOAD

Rofail D¹ , Viala M², Abetz L³, Gait C⁴

¹ Mapi Values Limited, Macclesfield, UK, ²Mapi Values France, Lyon, France, ³Mapi Values Limited, Bollington, UK, ⁴Mapi Values Ltd, Macclesfield, UK

PHM12

PHYSICIANS' PREFERENCES TOWARD COAGULATION FACTOR CONCENTRATES IN THE TREATMENT OF HEMOPHILIA PATIENTS WITH INHIBITORS: A DISCRETE CHOICE EXPERIMENT

Lee WC¹ , Joshi AV², Brown M³, Hadker N³, Sumner M², Pashos CL³

¹ Abt Associates Inc, Bethesda, MD, USA, ²Novo Nordisk Inc, Princeton, NJ, USA, ³Abt Associates Inc, Lexington, MA, USA

PHM13

SATISFACTION WITH IRON CHELATION THERAPY AND ITS IMPACT ON ADHERENCE IN PATIENTS WITH BETA THALASSEMIA MAJOR: RESULTS FROM THE ITHACA STUDY

¹ Mapi Values Limited, Macclesfield, UK, ²Center of Pharmacoeconomics, University of Milan, Milan, Italy, ³University of Milan, Milan, Italy, ⁴Congenital Anemia Center, IRCSS Foundation Policlinico, Mangiagalli, Regina Elena Hospitals and University of Milan, Milan, Italy, ⁵University of Naples, Federico II, Naples, Italy

PHM14

PATIENT PREFERENCE AND WILLINGNESS-TO-PAY FOR ANTICOAGULANT TREATMENT OPTIONS IN PATIENTS RECEIVING ORAL ANTICOAGULANT TREATMENT (OAT): A DISCRETE CHOICE EXERCISE

Monzini MS¹, Moia M², Carpenedo M², Mantovani LG³

Cost Studies

PIH1

BUDGET IMPACT ANALYSIS OF AVODART (DUTASTERIDE) IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN POLAND

¹ Arcana Institute, Cracow, Poland, ²GSK Commercial Sp. z o.o, Warsaw, Poland

PIH2

HEALTH ECONOMIC CONSEQUENCES OF THE CHOICE OF FOLLICLE STIMULATING HORMONE ALTERNATIVES IN IVF TREATMENT

Poulsen PB¹, Højgaard A², Quartarolo JP³

¹ MUUSMANN Research & Consulting AS, Kolding, Denmark, ²Randers Centralsygehus, Randers, Denmark, ³Ferring Scandinavia, Copenhagen, Denmark

PIH3

VACCINATION WITH RIX4414 IS COST-EFFECTIVE IN A BELGIAN SETTING

Fruytier A¹, Van Schoor J², Standaert B³

¹ UCL, Marche, Luxembourg, Belgium, ²GlaxoSmithKline Belgium, Genval, Brabant, Belgium, ³GlaxoSmithKline Biologicals, Rixensart, Belgium

PIH4

THE COST EFFECTIVENESS OF IVF IN ITALY: IMPLICATIONS OF A NEW LAW

Dale PL

PIH5

COST-EFFECTIVENESS OF DUTASTERIDE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)

¹ Arcana Institute, Cracow, Poland, ²GSK Commercial Sp. z o.o, Warsaw, Poland

PIH6

ECONOMIC EVALUATION OF CARBETOCINE FOR THE PREVENTION OF UTERINE ATONY IN PATIENTS WITH RISK FACTORS IN MEXICO

Del Angel-García G¹, Garcia-Contreras F², Constantino-Casas P², Nevarez-Sida A², Lopez-Gonzalez N³, García-Constantino M¹, Zuñiga M³

¹ Instituto Mexicano del Seguro Social, México City, Mexico City, Mexico, ²Mexican Institute of Social Security, México, Distrito Federal, Mexico, ³Mexican Institute of Social Security, México City, Mexico City, Mexico

PIH7

COST-EFFECTIVENESS OF SINGLE-EMBRYO-TRANSFER (SET) VERSUS DOUBLE-EMBRYO-TRANSFER (DET) STRATEGIES IN IN-VITRO FERTILIZATION

Poulsen PB¹, Ingerslev HJ², Kesmodel U³, Højgaard A⁴, Pinborg A⁵, Henriksen TB⁶, Ottosen LD⁴

¹ MUUSMANN Research & Consulting AS, Kolding, Denmark, ²Fertility Clinic, Aarhus University Hospital, Århus N, Denmark, ³Institute of Epidemiology and Social Medicine, University of Aarhus, Aarhus, Denmark, ⁴Fertility Clinic, Aarhus University Hospital, Aarhus N, Denmark, ⁵Fertility Clinic, Rigshospitalet, Copenhagen, Denmark, ⁶Department of Paediatrics, Aarhus University Hospital, Aarhus N, Denmark

PIH8

PROPORTION OF HERPES ZOSTER (HZ) PATIENTS DEVELOPING POST-HERPETIC NEURALGIA (PHN) AND ITS MANAGEMENT IN THE UK

Gauthier A¹, Remy V², Martin M¹, Pedalino B²

¹ i3 Innovus, Uxbridge, Middlesex, UK, ²Sanofi Pasteur MSD, Lyon, France

PIH9

THE ECONOMIC BURDEN OF DRUGS FOR CHILDREN CARE IN GENERAL PRACTICE: AN OBSERVATIONAL STUDY IN FRANCE

Pelletier-Fleury N¹, Le Vaillant M², Rosman S³, Franc C³

¹ Cermes, Inserm U750 (National Institute of Health and Medical Research), Le Kremlin Bicêtre, France, ²Cermes, Inserm U750 (National Institute of Health and Medical Research), Le kremlin Bicêtre, France, ³Cermes, Inserm U 750 (National Institute of Health and Medical Research), Le Kremlin Bicêtre, France

PIH10

SERVICE UTILIZATION AND HEALTH CARE COSTS OF THE ELDERLY POPULATION IN GERMANY

Heinrich S, Luppa M, Angermeyer MC, Riedel-Heller SG, Koenig HH

Health Care Use & Policy Studies

PIH11

EXPENDITURES ON PHARMACEUTICALS: DEMOGRAPHIC CHANGE AND INNOVATION - AN EMPIRICAL ANALYSIS

Ilgin Y, Eisen R

PIH12

THE DETERMINANTS OF DRUGS PRESCRIPTION FOR CHILDREN IN GENERAL PRACTICE

Franc C¹ , Le Vaillant M², Rosman S¹, Pelletier-Fleury N³

¹ Cermes, Inserm U 750 (National Institute of Health and Medical Research), Le Kremlin Bicêtre, France, ²Cermes, Inserm U750 (National Institute of Health and Medical Research), Le kremlin Bicêtre, France, ³Cermes, Inserm U750 (National Institute of Health and Medical Research), Le Kremlin Bicêtre, France

Methods & Concepts

PIH13

PHARMACOECONOMIC ASPECTS OF REFORMS OF PHARMACEUTICAL SECTOR\: MONTENEGRO EXPERIENCE

¹ Health Fund Montenegro, Podgorica, -, Serbia and Montenegro, ²Faculty of Medicine, Novi Sad, Vojvodina, Serbia and Montenegro, ³Medical faculty, Novi Sad, Vojvodina, Serbia and Montenegro, ⁴Economic faculty, Podgorica, Serbia and Montenegro, ⁵Medical faculty, Novi sad, Vojvodina, Serbia and Montenegro

PIH14

DETECTION OF SEMANTIC AMBIGUITY IN THE ITALIAN CHILD-FRIENDLY EQ-5D VERSION

¹ University of Bologna, Bologna, Italy, ²University of Bologna, Bologna, Italy, Italy, ³Health Authority of Bologna, Bologna, Italy, ⁴Centre of Pharmacoeconomics, University of Milan, Milan, Milan, Italy

PIH15

DEVELOPMENT OF AN ICIQ NOCTURNAL ENURESIS QOL QUESTIONNAIRE

Holm-Larsen T¹, Hansson M², Riis A³, Gennaro M⁴, Hagstrom S⁵, Nørgaard JP⁶

¹ University of Pharmaceutical Sciences, Copenhagen, Denmark, ²Ferring Pharmaceuticals A/S, Copenhagen, Denmark, ³Ferring Pharmaceuticals A/S, Copenhagen S, Denmark, ⁴Bambino Gesù Children's Hospital, Rome, Italy, ⁵Hospital of skejby, Aarhus, Denmark, ⁶Ferring Pharmaceuticals, Copenhagen, Denmark

Patient Reported Outcomes

PIH16

TREATMENT DURATION FOR ATROPHIC VAGINITIS: CLINICAL TRIALS VERSUS “THE REAL WORLD”

Balu S¹ , Lee WC², Joshi AV³, Cobden D³, Pashos CL¹

¹ Abt Associates Inc, Lexington, MA, USA, ²Abt Associates Inc, Bethesda, MD, USA, ³Novo Nordisk Inc, Princeton, NJ, USA

PIH17

ASSESSING PSYCHOLOGICAL BURDEN AND TREATMENT BENEFITS IN PEDIATRIC PATIENTS WITH BEDWETTING

Weinstein D¹, Sendersky V¹, Holm-Larsen T², Nørgaard JP¹

¹ Ferring Pharmaceuticals, Copenhagen, Denmark, ²University of Pharmaceutical Sciences, Copenhagen, Denmark

PIH18

DIMENSIONS OF HRQOL AND SATISFACTION WITH LIFE IMPROVE IN ED PATIENTS SWITCHING FROM OTHER ORAL ED MEDICATION TO TADALAFIL

Taipale K¹ , Fugl-Meyer A², Leinonen M³, Leinonen ES¹, Sintonen H⁴

¹ OY Eli Lilly Finland Ab, Vantaa, Finland, ²University of Uppsala, Uppsala, Sweden, ³OY 4Pharma Ltd, Kista, Sweden, ⁴University of Helsinki, Helsinki, Finland

PIH19

ESTIMATING UTILITY IN ROTAVIRUS GASTROENTERITIS IN CHILDREN UNDER FIVE IN THE UK

Martin A¹ , Cotrell S²

¹ GlaxoSmithKline UK Limited, Uxbridge, UK, ²IMS Health, London, England

PIH20

CONJOINT-ANALYSIS QALYS FOR ACUTE CONDITIONS:

Johnson FR, Hauber B, Ozdemir S

PIH21

INFLUENCE OF CONCOMITANT DISEASES ON THE CLINICAL RESPONSE TO TREATMENT FOR ERECTILE DYSFUNCTION

Gutiérrez del Pozo R¹, Cardeñosa O², Pérez M³, Artés M³

¹ Hospital Clínic, Barcelona, Spain, ²Q.F Bayer, Barcelona, Spain, ³Adelphi Targis, Barcelona, Spain

PIH22

LINGUISTIC VALIDATION OF THE MENSTRUAL DISTRESS QUESTIONNAIRE (MDQ) IN AN INTERNATIONAL STUDY FOR A NEW COMBINED ORAL CONTRACEPTIVE PILL

Fernandez N¹, Mear I², Moos R³, Johannes EJ⁴

¹ Mapi Reserach Institute, Lyon, France, ²Mapi Research Institute, Lyon, France, ³Standford School of Medicine, Stanford, CA, USA, ⁴ORGANON, BH Oss, The Netherlands

PIH23

ERECTILE DYSFUNCTION IN SPAIN: CLINICAL RESPONSE TO TREATMENTS

Gutiérrez del Pozo R¹, Cardeñosa O², Pérez M³, Artés M³

¹ Hospital Clínic, Barcelona, Spain, ²Q.F Bayer, Barcelona, Spain, ³Adelphi Targis, Barcelona, Spain

PIH24

PREFERENCES IN ITALIAN BPH PATIENTS

Arpinelli F¹, Pitrelli A¹, Oprandi N², Niero M²

¹ GlaxoSmithKline S.p.A, Verona, Italy, ²University of Verona, Verona, Italy

PIH25

THE COUPLE-PROJECT: POOLED ANALYSIS OF SATISFACTION WITH VARDENAFIL TREATMENT IN MEN WITH ERECTILE DYSFUNCTION AND THEIR PARTNERS

Evers T

Clinical Outcomes Studies

PRS1

PREVALENCE AND TREATMENT OF COPD IN GERMANY

Höer A¹ , Gothe H¹, Storz P¹, Sandtmann R², Häussler B¹

¹ IGES GmbH, Berlin, Germany, ²Altana Pharma AG, Konstanz, Germany

PRS2

EFFECT OF DRG IMPLEMENTATION IN GERMANY - ANALYSIS OF LENGTH OF HOSPITAL STAY OF IN-PATIENTS SUFFERING FROM COMMUNITY-ACQUIRED PNEUMONIA

¹ St. Josef Krankenhaus Haan GmbH, Haan, NRW, Germany, ²Bayer Vital GmbH, Leverkusen, NRW, Germany, ³Institute of Empirical Health Economics, Burscheid, NRW, Germany, ⁴Zentrum für Pneumologie und Thoraxchirurgie Heckeshorn, Berlin, Berlin, Germany

Cost Studies

PRS3

COST-EFFECTIVENESS OF ROFLUMILAST IN THE UK: A 1-YEAR STUDY IN PATIENTS WITH SEVERE TO VERY SEVERE COPD

¹ Erasmus MC, Rotterdam, The Netherlands, ²ALTANA Pharma AG, Konstanz, Germany

PRS4

THE COST-EFFECTIVENESS OF DRUG THERAPY IN COMMUNITY-ACQUIRED PNEUMONIA AND THE IMPACT OF ANTIMICROBIAL RESISTANCE IN GERMANY

Martin M¹ , Quilici S¹, Evers T², Kubin M²

¹ i3 Innovus, Uxbridge, Middlesex, UK, ²Bayer Healthcare AG, Wuppertal, Germany

PRS5

COSTS OF COPD EXACERBATIONS IN POLAND (RESULTS OF THE PILOT STUDY)

Jahnz-Rozyk KM, Targowski T, From S

PRS6

CONSEQUENCES FOR DRG-IMPLEMENTATION IN GERMANY: EFFECT ON DIRECT COSTS OF IN-PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA FROM HOSPITAL'S PERSPECTIVE

¹ St. Josef Krankenhaus Haan GmbH, Haan, NRW, Germany, ²Bayer Vital GmbH, Leverkusen, NRW, Germany, ³Institute of Empirical Health Economics, Burscheid, NRW, Germany, ⁴Zentrum für Pneumologie und Thoraxchirurgie Heckeshorn, Berlin, Berlin, Germany

PRS7

ESTIMATION OF MORBIDITY, RESOURCE UTILIZATION AND COST IN SUBJECTS TREATED WITH TIOTROPIUM BROMIDE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN A SPANISH POPULATION SETTING.

Sicras A¹ , Navarro R¹, De Haro L², Serrat J¹, Llopart J¹, Velasco S¹

¹ Badalona Serveis Assistencials, Badalona, Barcelona, Spain, ²Hospital Universitario Germans Trías y Pujol, Badalona, Barcelona, Spain

PRS8

RISK OF HOSPITALIZATIONS AND/OR EMERGENCY DEPARTMENT VISITS FOR MEDICAID PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): COMPARISON OF CONTROLLERS

Rascati KL¹, Akazawa M², Stanford RH²

¹ University of Texas at Austin, Austin, TX, USA, ²GlaxoSmithKline, Research Triangle Park, NC, USA

Health Care Use & Policy Studies

PRS9

CLINICAL PRACTICE VS GOLD RECOMMENDATIONS IN THE MANAGEMENT OF COPD PATIENTS: AN ECONOMIC ANALYSIS OF THE LACK OF ADHERENCE TO GUIDELINES.

Brosa M¹ , Miravitlles M², Crespo C³, Gobartt E⁴

¹ Oblikue Consulting, Barcelona, SC, Spain, ²Hospital Clínic, Barcelona, Barcelona, Spain, ³Oblikue Consulting, Barcelona, Spain, ⁴Boehringer Ingelheim España, S.A, Sant Cugat del Vallès (Barcelona), Spain

PRS10

PREVALENCE OF PULMONARY HYPERTENSION IN GERMANY – ESTIMATIONS BASED ON A TOP-DOWN APPROACH

Ehlken B¹ , Plesnila-Frank C¹, Ghofrani HA², Grimminger F², Hoeper MM³, Stähler G⁴, Wilkens H⁵, Berger K¹, Resch A⁶

¹ MERG-Medical Economics Research Group, Munich, Germany, ²University Hospital Giessen and Marburg, Giessen, Germany, ³Hannover Medical School, Hanover, Germany, ⁴Klinik Löwenstein, Löwenstein, Germany, ⁵University Hospitals of the Saarland, Homburg/Saar, Germany, ⁶Pfizer Deutschland GmbH, Karlsruhe, Germany

PRS11

THE TREATMENT OF RESPIRATORY DISEASES AND HEALTH CARE BUDGET IMPACT WITHIN SLOVAKIA

Tesar T¹ , Foltan V¹, Tomek D²

¹Comenius University, Bratislava, Slovak Republic, ²Health Insurance fund APOLLO, Bratislava, Slovak Republic

Methods & Concepts

PRS12

EXPECTED VALUE OF PERFECT INFORMATION: A PRACTICAL EXAMPLE OF REDUCING DECISION UNCERTAINTY BY CONDUCTING ADDITIONAL RESEARCH

Oostenbrink JB, Rutten-van Molken M, Oppe M, Al MJ

PRS13

USING PATIENT DESCRIPTORS TO DEVELOP A PRO MEASUREMENT STRATEGY FOR CLINICAL TRIALS: EVALUATING THE COPD PATIENT'S EXPERIENCE OF DYSPNEA

Martin M¹ , Bushnell D², Gilbert C³, Patrick D⁴, Schunemann H⁵, Hareendran A³

¹ Health Research Associates, Inc, Seattle, WA, USA, ²Health Research Associates, Mountlake Terrace, WA, USA, ³Pfizer, Ltd, Sandwich, Kent, UK, ⁴University of Washington, Seattle, WA, USA, ⁵Italian National Cancer Institute, Rome, Rome, Italy

Patient Reported Outcomes

PRS14

PERSISTENCE WITH TIOTROPIUM: A COMPARISON WITH ESTABLISHED MEDICATIONS FOR COPD

¹ PHARMO Institute, Utrecht, The Netherlands, ²Pfizer Inc, New York, NY, USA, ³Boehringer-Ingelheim, Ridgefield, CT, USA

PRS15

IMPROVING THE PERSISTENCE OF PATIENTS UNDERGOING SUBLINGUAL IMMUNOTHERAPY: SCORING AND VALIDATION OF A PATIENT-MANAGEMENT TOOL

Arnould B¹ , Viala M¹, Benmedjahed K¹, Fadel R², Bos C², Didier A³, Vervloet D⁴

¹ Mapi Values France, Lyon, France, ²Laboratoire Stallergènes, Antony, France, ³Rangueil-Larrey Hospital, Toulouse, France, ⁴Sainte-Marguerite Hospital, Marseille, France

PRS16

MEASURING THE IMPACT OF COPD ON PATIIENTS' LIVES IN AN INTERNATIONAL STUDY

Mear I¹ , Miege A¹, Roulliat C¹, Gyuatt G², Schunemann H³, Jost FJ⁴, Zamora LMZ⁵

¹ Mapi Research Institute, Lyon, France, ²McMaster University Health Sciences, Hamilton, ON, Canada, ³McMaster University, Buffalo, NY, USA, ⁴Roche, Basel, Swaziland, ⁵Roche, Nutley, NJ, USA

PRS17

VALIDATION OF THE COPD SEVERITY SCORE FOR USE IN THE SPANISH PRIMARY HEALTH CARE SYSTEM, THE NEREA STUDY: PRELIMINARY RESULTS

Ferrer M¹ , Miravitlles M², Llor C³, Donado E⁴

¹ 3D Health Research, Barcelona, Barcelona, Spain, ²Hospital Clínic, Barcelona, Spain, ³Centre d'Atenció Primaria Jaume I, Tarragona, Spain, ⁴J. Uriach & CIA S.A, Palau- Solità i Plegamans, Barcelona, Spain

PRS18

MEASURING DISEASE-SPECIFIC UTILITIES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE HEALTH- AND EXACERBATION PROFILES

Rutten- van Molken M, Hoogendoorn-Lips M, Lamers L

PRS19

EPIDEMIOLOGICAL STUDY TO INVESTIGATE PATIENTS' VIEWS ON CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

¹ SOTIRIA Chest Hospital, Athens, Greece, ²AstraZeneca SA, Athens, Greece

Clinical Outcomes Studies 

PSK1

Withdrawn
 

Cost Studies

PSK2

MEDICATION ADHERENCE AND HEALTH CARE COSTS ASSOCIATED WITH BIOLOGICS IN MEDICAID-ENROLLED PATIENTS WITH PSORIASIS

Balkrishnan R¹, Bhosle MJ¹, Nahata MC¹, Feldman SR²

¹ The Ohio State University College of Pharmacy, Columbus, OH, USA, ²Wake Forest University School of Medicine, Winston Salem, NC, USA

PSK3

A COST-EFFECTIVENESS ANALYSIS OF BIOLOGIC THERAPIES FOR THE TREATMENT OF CHRONIC PLAQUE PSORIASIS

Roberts G¹ , Morris J²

¹ Oxford Outcomes Ltd, Oxford, Oxfordshire, UK, ²Schering-Plough Ltd, Welwyn Garden City, Hertfordshire, UK

PSK4

COST-EFFECTIVENESS OF TOPICAL CALCIPOTRIOL/BETAMETHASONE DIPROPIONATE TWO-COMPOUND PRODUCT IN A SCOTTISH CARE MODEL

¹ Falkirk & District Royal Infirmary, Falkirk, Scotland, UK, ²LEO Pharma, Princes Risborough, Buckinghamshire, England, ³LEO Pharma, Ballerup, Denmark

PSK5

COST OF ATOPIC DERMATIS IN ADULTS: THE CODA STUDY

De Portu S¹, Scalone L², Monzini MS², Ziccardi M¹, Baranzoni N³, Giannetti A³, Mantovani LG¹

¹ University of Naples, Federico II, Naples, Italy, ²University of Milan, Milan, Italy, ³Policlinico Hospital, University of Modena and Reggio Emilia, Modena, Italy

Health Care Use & Policy Studies

PSK6

BELGIAN DRUG UTILISATION STUDY OF ELIDEL^® IN ROUTINE PRACTICE IN ATOPIC DERMATITIS

Lecomte P¹ , Lambert J², Degreef H³, Lesaffre E⁴, De Backer M¹

¹ Novartis Pharmaceuticals, Vilvoorde, Belgium, ²UZ-Antwerpen, Antwerpen, Belgium, ³UZ-St Rafaël, Leuven, Belgium, ⁴Biostatistical Centre KULeuven, Leuven, Belgium

Methods & Concepts

PSK7

CONVERGENT VALIDITY AND SENSITIVITY TO CHANGE OF GENERIC AND DISEASE-SPECIFIC INSTRUMENTS USED IN CHILDREN WITH ATOPIC DERMATITIS

Scalone L¹ , De Portu S², Casati A³, Colonna C⁴, Monzini MS¹, Gelmetti C⁴, Mantovani LG²

¹ Centre of Pharmacoeconomics, Milan, Milan, Italy, ²University of Naples, Federico II, Naples, Naples, Italy, ³Centre of Pharmacoeconomics, Milan, Milan, Italy, ⁴IRCCS Policlinico, Hospitals Mangiagalli & Regina Elena Foundation, Milan, Milan, Italy

PSK8

CONVERGENT VALIDITY AND SENSITIVITY TO CHANGE OF THE GENERIC INSTRUMENT EQ-5D AND THE DISEASE-SPECIFIC DLQI IN ATOPIC DERMATITIS

Scalone L¹ , De Portu S², Casati A³, Baranzoni N⁴, Monzini MS¹, Giannetti A⁴, Mantovani LG²

¹ Centre of Pharmacoeconomics, Milan, Milan, Italy, ²University of Naples, Federico II, Naples, Naples, Italy, ³Centre of Pharmacoeconomics, Milan, Milan, Italy, ⁴Policlinico Hospital, University of Modena and Reggio Emilia, Modena, Modena, Italy

Patient Reported Outcomes

PSK9

QUALITY OF LIFE OF ADULT PATIENTS WITH ATOPIC DERMATITIS: THE CODA STUDY

Scalone L¹ , De Portu S², Casati A³, Baranzoni N⁴, Monzini MS¹, Giannetti A⁴, Mantovani LG²

¹ Centre of Pharmacoeconomics, University of Milan, Milan, Italy, ²University of Naples, Federico II, Naples, Italy, ³Centre of Pharmacoeconomics, University of Milan, Milan, Italy, ⁴Policlinico Hospital, University of Modena and Reggio Emilia, Modena, Italy

PSK10

OVERCOMING DIFFERENTIAL ITEM FUNCTIONING ASSOCIATED WITH MEASURING PATIENT REPORTED OUTCOMES IN MULTINATIONAL CLINICAL TRIALS

McKenna SP, Meads D, Doward LC

Galen Research, Manchester, UK

PSK11

CARE GIVERS' WILLINGNESS TO PAY FOR DIFFERENT CHARACTERISTICS OF THE ATOPIC DERMATITIS TREATMENT

Monzini MS¹, De Portu S², Scalone L¹, Colonna C³, Gelmetti C³, Mantovani LG²

¹ University of Milan, Milan, Italy, ²University of Naples, Federico II, Naples, Italy, ³IRCCS Policlinico, Hospitals Mangiagalli & Regina Elena Foundation, Milan, Italy